GN Store Nord and Amplifon have announced that all regulatory approvals have been secured for Amplifon’s planned acquisition of GN’s hearing aid business, bringing the companies one step closer to completing one of the hearing industry’s largest transactions of 2026. The final approval came from the European Commission, following earlier clearances in the United States and Australia....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a regulatory and business milestone with no immediate clinical practice implications, though the consolidation may affect product availability and brand relationships over time.
This acquisition represents a significant consolidation of the global hearing aid supply chain, potentially reshaping manufacturer-retailer relationships and competitive dynamics for independent clinics.
- 01All regulatory approvals for Amplifon's acquisition of GN's hearing aid business have been secured.
- 02Deal closing is expected by year-end 2026.
- 03The merger combines GN's hearing aid manufacturing arm with Amplifon's global retail network.
- 04This consolidation could affect independent clinic access to GN/ReSound products.
- 05Regulatory clearance across multiple jurisdictions suggests the deal survived antitrust scrutiny.
All regulatory approvals for the GN–Amplifon acquisition have been secured.
press releasesupportedThe deal closing is expected by year-end 2026.
press releasesupported
